{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:49:37Z","timestamp":1776926977044,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Prenatal screening for chromosome aneuploidies have constantly been evolving, especially with the introduction of cell-free fetal DNA (cfDNA) screening in the most recent years. This study compares the performance, costs and timing of test results of three cfDNA screening implementation strategies: contingent, reflex and primary.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We modelled enhanced first trimester screening (eFTS) as the first-tier test in contingent or reflex strategies. cfDNA test was performed contingent on or reflex from eFTS results. A comparison was made between cfDNA screening using sequencing technology and Rolling Circle Amplification (RCA)\/imaging solution. All model assumptions were based on results from previous publications or information from the Ontario prenatal screening population.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At an eFTS risk cut-off of \u22651\/1000, contingent and reflex cfDNA screening have the same detection rate (DR) (94%) for trisomy 21. Reflex cfDNA screening using RCA\/Imaging solution provided the lowest false positive rate and cost. The number of women requiring genetic counselling and diagnostic testing was significantly reduced and women received their cfDNA screening result 9\u2009days sooner compared with the contingent model. While primary cfDNA screening improved the trisomy 21 DR by 3\u20135%, it was more costly and more women required diagnostic testing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Reflex cfDNA screening is the most cost-effective prenatal screening strategy. It can improve the efficiency of prenatal aneuploidy screening by reducing the number of patient visits and providing more timely results.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12884-020-03394-w","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T14:05:23Z","timestamp":1606140323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-2638","authenticated-orcid":false,"given":"Tianhua","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamim","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan K.","family":"Priston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Melanie","family":"Bedford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Mak-Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy S.","family":"Meschino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"9125","key":"3394_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(97)11280-6","volume":"352","author":"RJ Snijders","year":"1998","unstructured":"Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation first trimester screening group. Lancet. 1998;352(9125):343\u20136.","journal-title":"Lancet."},{"key":"3394_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/096914130301000302","volume":"10","author":"AM Summers","year":"2003","unstructured":"Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR. Maternal serum screening in Ontario using the triple marker test. J Med Screen. 2003;10:107\u201311.","journal-title":"J Med Screen"},{"key":"3394_CR3","doi-asserted-by":"publisher","first-page":"c7401","DOI":"10.1136\/bmj.c7401","volume":"342","author":"RW Chiu","year":"2011","unstructured":"Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011;342:c7401.","journal-title":"BMJ."},{"key":"3394_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/pd.4686","volume":"35","author":"R Stokowski","year":"2015","unstructured":"Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ. Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. Prenat Diagn. 2015;35:1243\u20136.","journal-title":"Prenat Diagn"},{"key":"3394_CR5","doi-asserted-by":"publisher","unstructured":"Ericsson O, Ahola T, Dahl F, et al. Clinical validation of a novel automated cell-free DNA screeningassay for trisomies 21, 13, and 18 in maternal plasma. Prenat Diagn. 2019. https:\/\/doi.org\/10.1002\/pd.5528 [Epub ahead of print] PubMed PMID: 31429096.","DOI":"10.1002\/pd.5528"},{"key":"3394_CR6","first-page":"249e66","volume":"45","author":"MM Gil","year":"2015","unstructured":"Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45:249e66.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR7","doi-asserted-by":"crossref","unstructured":"Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG. 2017;124:32\u201346.","DOI":"10.1111\/1471-0528.14050"},{"key":"3394_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/pd.4597","volume":"35","author":"T Huang","year":"2015","unstructured":"Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein a, free-\u03b2 human chorionic gonadotrophin, placental growth factor, and \u03b1-fetoprotein. Prenat Diagn. 2015;35:709\u201316.","journal-title":"Prenat Diagn"},{"key":"3394_CR9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/gim.2018.22","volume":"20","author":"GE Palomaki","year":"2018","unstructured":"Palomaki GE, Kloza EM. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. Genet Med. 2018;20:1312\u201323.","journal-title":"Genet Med."},{"key":"3394_CR10","first-page":"4549.11","volume":"8","author":"F Dahl","year":"2018","unstructured":"Dahl F, Ericsson O, Karlberg O, et al. Imaging single DNA molecules for high precision NIPT. Sci Rep. 2018;8:4549.11.","journal-title":"Sci Rep"},{"key":"3394_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/uog.15783","volume":"47","author":"MM Gil","year":"2016","unstructured":"Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol. 2016;47:45\u201352.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR12","unstructured":"The non-invasive prenatal test (NIPT) is now available for every pregnant woman in the Netherlands https:\/\/www.amsterdamresearch.org\/web\/instituut-1\/nieuws\/tonenop\/the-non-invasive-prenatal-test-nipt-is-now-available-for-every-pregnant-woman-in-the-netherlands-.htm Accessed 6 Mar 2019."},{"key":"3394_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058732","volume":"8","author":"NJ Wald","year":"2013","unstructured":"Wald NJ, Bestwick JP. Incorporating DNA sequencing into current prenatal screening practice for Down's syndrome. PLoS One. 2013;8:e58732.","journal-title":"PLoS One"},{"key":"3394_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/pd.4609","volume":"35","author":"GE Palomaki","year":"2015","unstructured":"Palomaki GE, Eklund EE, Neveux LM, Lambert Messerlian GM. Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures. Prenat Diagn. 2015;35:789\u201396.","journal-title":"Prenat Diagn"},{"issue":"7","key":"3394_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220053","volume":"14","author":"JP Bestwick","year":"2019","unstructured":"Bestwick JP, Wald NJ. Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13. PLoS One. 2019;14(7):e0220053. https:\/\/doi.org\/10.1371\/journal.pone.0220053 eCollection 2019. PubMed PMID: 31344071; PubMed Central PMCID: PMC6658079.","journal-title":"PLoS One"},{"key":"3394_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/uog.14693","volume":"45","author":"MI Evans","year":"2015","unstructured":"Evans MI, Sonek JD, Hallahan TW, Krantz DA. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. Ultrasound Obstet Gynecol. 2015;45:74\u201383.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jogc.2017.01.025","volume":"39","author":"T Huang","year":"2017","unstructured":"Huang T, Meschino WS, Teitelbaum M, Dougan S, Okun N. Enhanced first trimester screening for trisomy 21 with contingent cell-free fetal DNA: a comparative performance and cost analysis. J Obstet Gynaecol Can. 2017;39:742\u20139.","journal-title":"J Obstet Gynaecol Can"},{"key":"3394_CR18","unstructured":"Current Criteria for Publicly Funded Non-invasive Prenatal Testing (NIPT) in Ontario https:\/\/prenatalscreeningontario.ca\/current-criteria-for-publicly-funded-non-invasive-prenatal-testing-nipt-in-ontario\/ Accessed 18 Mar 2019."},{"key":"3394_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/pd.2403","volume":"30","author":"GM Savva","year":"2010","unstructured":"Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn. 2010;30:57\u201364.","journal-title":"Prenat Diagn"},{"key":"3394_CR20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-0528.1996.tb09609.x","volume":"103","author":"MC Macintosh","year":"1996","unstructured":"Macintosh MC, Wald NJ, Chard T, et al. The selective miscarriage of Down\u2019s syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol. 1996;103:1172\u20133.","journal-title":"Br J Obstet Gynaecol"},{"key":"3394_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/uog.14636","volume":"45","author":"R Akolekar","year":"2015","unstructured":"Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;45:16\u201326.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR22","unstructured":"Prenatal Tests, https:\/\/www.dynacare.ca\/patients-and-individuals\/health-solutions\/prenatal-tests.aspx. Accessed 18 Mar 2019."},{"key":"3394_CR23","unstructured":"Panorama\u2122 Non-Invasive Prenatal Testing (NIPT) https:\/\/www.lifelabsgenetics.com\/product\/non-invasive-prenatal-testing. Accessed 18 Mar 2019."},{"key":"3394_CR24","unstructured":"Vanadis\u00ae NIPT system: Proof of principle data for trisomy screening, White paper, PerkinElmer, Inc. 2018.\u00a0https:\/\/www.perkinelmer.com\/lab-solutions\/resources\/docs\/WHP_Vanadis-NIPT_Clinical_013891_01.pdf. Accessed 13 Nov 2020."},{"key":"3394_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jogc.2018.01.007","volume":"40","author":"T Huang","year":"2018","unstructured":"Huang T, Meschino WS, Rashid S, Dennis A, Mak-Tam E, Cuckle H. Enhanced first trimester aneuploidy screening with placental growth factor and alpha Feto-protein: detection of trisomies 18 and 13. J Obstet Gynaecol Can. 2018;40:1295\u2013301.","journal-title":"J Obstet Gynaecol Can"},{"key":"3394_CR26","first-page":"40","volume":"36","author":"KO Kagan","year":"2015","unstructured":"Kagan KO, Hoopmann M, Hammer R, Stressig R, Kozlowski P. Screening for chromosomal abnormalities by first trimester combined screening and noninvasive prenatal testing. Ultraschall Med. 2015;36:40\u20136.","journal-title":"Ultraschall Med"},{"key":"3394_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358388","volume":"35","author":"A Syngelaki","year":"2014","unstructured":"Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther. 2014;35:174\u201384.","journal-title":"Fetal Diagn Ther"},{"key":"3394_CR28","first-page":"2905","volume":"30","author":"E Colosi","year":"2017","unstructured":"Colosi E, D'Ambrosio V, Periti E. First trimester contingent screening for trisomies 21,18,13: is this model cost efficient and feasible in public health system? J Matern Fetal Neonatal Med. 2017;30:2905\u201310.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"3394_CR29","doi-asserted-by":"publisher","first-page":"i3426","DOI":"10.1136\/bmj.i3426","volume":"354","author":"LS Chitty","year":"2016","unstructured":"Chitty LS, Wright D, Hill M, et al. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down\u2019s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units. BMJ. 2016;354:i3426.","journal-title":"BMJ"},{"key":"3394_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12962-019-0173-8","volume":"17","author":"JC Bay\u00f3n","year":"2019","unstructured":"Bay\u00f3n JC, Orru\u00f1o E, Portillo MI, Asua J. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2019;17:6.","journal-title":"Cost Eff Resour Alloc"},{"key":"3394_CR31","unstructured":"Perinatal Services BC, Obstetric Guideline: Prenatal Screening for Down Syndrome, Trisomy 18 and Open Neural Tube Defects, http:\/\/www.perinatalservicesbc.ca\/Documents\/Guidelines-Standards\/Maternal\/PrenatalScreeningGuideline.pdf Accessed 6 June 2019."},{"key":"3394_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/gim.2017.188","volume":"20","author":"NJ Wald","year":"2018","unstructured":"Wald NJ, Huttly WJ, Bestwick JP, et al. Prenatal reflex DNA screening for trisomies 21, 18, and 13. Genet Med. 2018;20:825\u201330.","journal-title":"Genet Med"},{"key":"3394_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/uog.17492","volume":"49","author":"H Cuckle","year":"2017","unstructured":"Cuckle H. cfDNA screening performance: accounting for and reducing test failures. Ultrasound Obstet Gynecol. 2017;49:689\u201392.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/uog.6123","volume":"32","author":"KO Kagan","year":"2008","unstructured":"Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy associated plasma protein-a. Ultrasound Obstet Gynecol. 2008;32:488\u201392.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"3394_CR35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/uog.15851","volume":"47","author":"R Revello","year":"2016","unstructured":"Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016;47(6):698\u2013704.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR36","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/pd.4397","volume":"34","author":"LC Poon","year":"2014","unstructured":"Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34:618\u201327.","journal-title":"Prenat Diagn"},{"key":"3394_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/uog.17455","volume":"49","author":"N O'Gorman","year":"2017","unstructured":"O'Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49:756\u201360.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3394_CR38","first-page":"3558","volume":"29","author":"N Maiz","year":"2016","unstructured":"Maiz N, Alzola I, Murua EJ, Rodr\u00edguez SJ. Cell-free DNA testing after combined test: factors affecting the uptake. J Matern Fetal Neonatal Med. 2016;29:3558\u201362.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"3394_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ajo.12778","volume":"58","author":"L Hui","year":"2018","unstructured":"Hui L, Barclay J, Poulton A, Hutchinson B, Halliday JL. Prenatal diagnosis and socioeconomic status in the non-invasive prenatal testing era: a population-based study. Aust N Z J Obstet Gynaecol. 2018;58:404\u201310.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"3394_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.clinbiochem.2012.06.015","volume":"45","author":"N Lepage","year":"2012","unstructured":"Lepage N, Chaudhry A, Konforte D, et al. Ontario prenatal screening program. Standardized Procedural Practices of the Ontario Prenatal Screening Program for aneuploidies and open neural tube defects. Clin Biochem. 2012;45:1152\u20137.","journal-title":"Clin Biochem"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-020-03394-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T14:15:47Z","timestamp":1606140947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-03394-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3394"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-03394-w","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Research Ethics Board of North York General Hospital ruled that no formal ethics approval was required in this particular study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors (Tianhua Huang, Wendy S. Meschino, Shamim Rashid and Ellen Mak-Tam) had received reagent kits for previous studies on multiple marker screening from PerkinElmer. The authors (Tianhua Huang, Melanie Bedford, Shamim Rashid\u00a0and Ellen Mak-Tam)\u00a0\u00a0have received a funding for study on pre-eclampsia screening from Thermo Fisher Scientific. The authors (Clare Gibbons and Wendy S. Meschino) are part of Validation of a Low Cost Aneuploidy Screening (VALUE) study and received funds for study activities (recruitment and sample collection). PerkinElmer and Thermo Fisher had no role in the design, data collection and analysis, and decision to publish the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"713"}}